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Cardiology

Cantu syndrome (CS) is characterized by multiple vascular and cardiac abnormalities
including vascular dilation and tortuosity, systemic hypotension, and cardiomegaly. The
disorder is caused by gain-of-function (GOF) mutations in genes encoding pore-forming
(Kir6.1, KCNJ8) and accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel
subunits. However, there is little understanding of the link between molecular dysfunction
and the complex pathophysiology observed, and there is no known treatment, in large part
due to the lack of appropriate preclinical disease models in which to test therapies. Notably,
expression of Kir6.1 and SUR2 does not fully overlap, and the relative contribution of KATP
GOF in various cardiovascular tissues remains to be elucidated. To investigate
pathophysiologic mechanisms in CS we have used CRISPR/Cas9 engineering to introduce
CS-associated SUR2[A478V] and Kir6.1[V65M] mutations to the equivalent endogenous
loci in mice. Mirroring human CS, both of these animals exhibit low systemic blood pressure
and dilated, compliant blood vessels, as well dramatic cardiac enlargement, the effects
being more severe in V65M animals than in A478V animals. In both animals, whole-cell
patch-clamp recordings reveal enhanced basal KATP conductance in vascular smooth
muscle, explaining vasodilation and lower blood pressure, and demonstrating a cardinal
role for smooth muscle KATP dysfunction in CS etiology. Echocardiography confirms in situ
cardiac enlargement and increased cardiac output in both animals. Patch-clamp recordings
reveal reduced ATP sensitivity of […]
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Cantu syndrome (CS) is characterized by multiple vascular and cardiac abnormalities including
vascular dilation and tortuosity, systemic hypotension, and cardiomegaly. The disorder is
caused by gain-of-function (GOF) mutations in genes encoding pore-forming (Kir6.1, KCNJ8) and
accessory (SUR2, ABCC9) ATP-sensitive potassium (KATP) channel subunits. However, there is
little understanding of the link between molecular dysfunction and the complex pathophysiology
observed, and there is no known treatment, in large part due to the lack of appropriate preclinical
disease models in which to test therapies. Notably, expression of Kir6.1 and SUR2 does not fully
overlap, and the relative contribution of KATP GOF in various cardiovascular tissues remains to
be elucidated. To investigate pathophysiologic mechanisms in CS we have used CRISPR/Cas9
engineering to introduce CS-associated SUR2[A478V] and Kir6.1[V65M] mutations to the equivalent
endogenous loci in mice. Mirroring human CS, both of these animals exhibit low systemic blood
pressure and dilated, compliant blood vessels, as well dramatic cardiac enlargement, the effects
being more severe in V65M animals than in A478V animals. In both animals, whole-cell patchclamp recordings reveal enhanced basal KATP conductance in vascular smooth muscle, explaining
vasodilation and lower blood pressure, and demonstrating a cardinal role for smooth muscle KATP
dysfunction in CS etiology. Echocardiography confirms in situ cardiac enlargement and increased
cardiac output in both animals. Patch-clamp recordings reveal reduced ATP sensitivity of ventricular
myocyte KATP channels in A478V, but normal ATP sensitivity in V65M, suggesting that cardiac
remodeling occurs secondary to KATP overactivity outside of the heart. These SUR2[A478V] and
Kir6.1[V65M] animals thus reiterate the key cardiovascular features seen in human CS. They
establish the molecular basis of the pathophysiological consequences of reduced smooth muscle
excitability resulting from SUR2/Kir6.1–dependent KATP GOF, and provide a validated animal model
in which to examine potential therapeutic approaches to treating CS.
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Cantu syndrome (CS) was first recognized as a distinct pathology 35 years ago (1). The syndrome is
extremely complex, with patients typically demonstrating a host of cardiovascular features including
marked cardiomegaly, vascular dilation and tortuosity, low blood pressure, persistence of fetal circulation,
and pulmonary hypertension (2–6), in addition to hypertrichosis and acromegaloid facial features (7, 8).
The molecular basis is now clear: CS results from mutations in the ABCC9 and KCNJ8 genes, which encode
the regulatory ABCC9 (SUR2) sulfonylurea receptor and pore-forming KCNJ8 (Kir6.1) subunits, respectively, of ATP-sensitive potassium (KATP) channels (9–12). Expressed in various tissues in the body, KATP
channels are nucleotide-gated, potassium-selective channels that couple cellular metabolism to electrical
excitability. KCNJ8 and ABCC9 are adjacent genes on human chromosome 12p12.1, and there is a paralogous pair of genes (KCNJ11 [Kir6.2] and ABCC8 [SUR1]) on chromosome 11p15.1, with the consequence
that multiple subunit combinations may be present in KATP channels in different tissues. Heterogeneity is
further increased by the existence of variably spliced SUR isoforms; particularly prominent are 2 major
splice isoforms of SUR2: SUR2A and SUR2B (13–15). KATP channels in vascular smooth muscle are predominantly formed of Kir6.1 and SUR2B, and regulate vascular tone and blood pressure (16, 17), whereas
Kir6.2 and SUR2A predominate in cardiac ventricular myocytes, wherein channel activation can result in
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Figure 1. Generation of the Cantu mice. (A)
Left: Structural representation of the pancreatic
Kir6.2/SUR1 KATP channel (PDB ID: 5WUA) with
the equivalent position of Kir6.1[V65M] and
SUR2[A478V] highlighted. Right: Predominant
isoform composition of vascular smooth muscle
(Kir6.1/SUR2B) and ventricular (Kir6.2/SUR2A)
KATP channels. (B) Sequencing chromatograms
from heterozygous Kir6.1wt/VM and SUR2wt/AV animals. (C) Kaplan-Meier survival curves for WT
and Cantu animals (n = 8–25 in each genotype).
(D) Body weight measurements from Kir6.1wt/VM,
Kir6.1VM/VM, and WT littermate mice prior to
weaning; Kir6.1VM/VM mice lose weight prior
to premature death at around 20 days (n =
15–25 animals). Statistical significance was
determined by multiway ANOVA followed by
t test pairwise comparison with Bonferroni’s
correction for multiple comparisons (adjusted α
= 0.05/3 = 0.017). *P < 0.05.

significant shortening of the ventricular action potential, which may be cardioprotective in conditions of
metabolic or ischemic stress (18, 19).
All identified Kir6.1 and SUR2 CS mutations result in enhanced activity of recombinant KATP channels
(20–23) and are therefore expected to result in KATP GOF in vivo, although this has not been established.
Channel GOF is in turn predicted to result in hyperpolarization of the membrane potential and thus a
primary decrease of excitability, in all relevant cell types. In smooth muscle, decreased excitability would
be predicted to cause vasorelaxation and lowering of blood pressure. In the myocardium, the naive prediction of KATP overactivity would be reduced action potential duration, shortening of the QT interval, and
reduced contractility as a consequence. How KATP overactivity results in the complex and diverse pathophysiology of CS is not trivially obvious and remains largely unexplained. Here, we report the generation
of CRISPR/Cas9–modified mice in which CS-associated mutations were introduced into native KCNJ8
and ABCC9 loci. These animals establish that both primary and secondary cardiovascular features of CS
specifically arise from consequences of GOF missense mutations in Kir6.1 and SUR2, and inform the consequences of vascular smooth muscle inexcitability more generally.

Results
Generation of CRISPR/Cas9–modified KCNJ8- and ABCC9-mutant mice. CS arises from GOF mutations in
KCNJ8 and ABCC9, the genes encoding the KATP channel subunits, Kir6.1 and SUR2, respectively. CRISPR/
Cas9 gene editing was used to introduce single-nucleotide mutations into the endogenous KCNJ8 and ABCC9
gene loci, resulting in protein substitutions that are analogous to Kir6.1[V65M] (V65M in mouse sequence)
and SUR2[A478V] (A476V in mouse sequence) in human CS patients (Figure 1, A and B; see Methods).
Founder animals were all viable and fertile, and were bred back to C57BL/6J WT mice to establish
several heterozygous lines of each genotype. Homozygous and heterozygous animals from generations F3
onwards were analyzed in all experiments below. There was a minor decrease in survival for heterozygous
Kir6.1[V65M] (Kir6.1wt/VM), heterozygous SUR2[A478V] mice (SUR2wt/AV), and homozygous SUR2[A478V]
(SUR2AV/AV) mice (Figure 1C). Crossing heterozygous animals from the 2 mutant lines also yielded doubleheterozygous Kir6.1wt/VM/SUR2wt/AV mice, which showed markedly increased mortality (Figure 1C). Survival
was drastically decreased in homozygous Kir6.1VM/VM mice (Figure 1C), which consistently lost weight prior
to dying, within a week or so after weaning (Figure 1D). Autopsy of Kir6.1VM/VM mice sacrificed at 3 weeks
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 2. Smooth muscle KATP channels
in Kir6.1wt/VM and SUR2wt/AV
mice. (A) Representative whole-cell
voltage-clamp recordings from acutely
isolated aortic smooth muscle cells
from WT (top) and Kir6.1wt/VM (bottom)
mice. Cells were voltage clamped at
–70 mV. (B) Representative wholecell voltage-clamp recordings from
Kir6.1wt/VM aortic smooth muscle cells
using an intracellular pipette solution
containing 5 mM ATP. (C) Summary
of whole-cell current densities from
voltage-clamp recordings of Kir6.1wt/VM
aortic smooth muscle cells showing significant increases in basal and pinacidilactivated KATP conductances, which are
resistant to glibenclamide inhibition
(n ≥ 5 for WT and 11 for Kir6.1wt/VM from
≥ 3 mice each). (D) Representative
whole-cell voltage-clamp recordings
from acutely isolated aortic smooth
muscle cells from WT (left, black), heterozygous SUR2wt/AV (middle, orange),
and homozygous SUR2AV/AV (right, red)
mice using an intracellular pipette
solution absent of nucleotides (–70 mV
holding potential). (E) Left: Summary
of whole-cell current densities from
voltage-clamp recordings of aortic
smooth muscle cells from WT, SUR2wt/AV,
and SUR2AV/AV mice showing significant
increases in basal and pinacidil-activated KATP conductances (n ≥ 8 for WT, 11
for SUR2wt/AV, and 14 for SUR2AV/AV from ≥
3 mice each). Right: Summary of experiments in which 5 mM ATP was included
in the patch pipette shown for WT and
SURAV/AV cells. Statistical significance
was determined by multiway ANOVA
followed by t test pairwise comparison
with Bonferroni’s correction for multiple
comparisons. Adjusted α = 0.008 (C)
and 0.003 (E). **P < 0.01.

of age revealed distended intestines which, when considered alongside the observed weight loss, may indicate
impaired gastrointestinal function.
Mutation of Kir6.1 and SUR2 results in GOF of native vascular smooth muscle KATP channels, but ventricular myocyte
KATP is only affected in SUR2-mutant mice. The effects of the introduced mutations on KATP channel function were
determined using patch-clamp electrophysiology. Firstly, whole-cell patch-clamp recordings, using an intracellular pipette solution containing no ATP (see Methods), revealed a markedly higher (~5-fold) basal potassium
conductance in acutely isolated aortic smooth muscle cells from Kir6.1wt/VM mice, compared with WT (Figure
2, A and C). Application of the KATP channel opener, pinacidil, provoked significant increase in conductance in
WT vascular smooth muscle cells (VSMCs), but this effect was blunted in VSMCs from V65M mice, reflecting
basal activation of the mutant KATP channels. Subsequent application of the KATP channel inhibitor, glibenclamide, markedly reduced the pinacidil-activated conductance in WT VSMCs, but was less effective in V65M
(Figure 2, A and C), potentially reflecting the reduced glibenclamide sensitivity of Kir6.1[V65M] channels
(21). Importantly, inclusion of a high concentration (5 mM) of ATP in the patch pipette essentially abolished
both basal and pinacidil-activated conductances in cells from both WT and V65M VSMCs (Figure 2, B and C),
confirming that the observed conductances resulted from KATP channel activity.
Because homozygous SUR2AV/AV mice survive to adulthood, we were able to analyze the effect of
the SUR2[A478V] mutation in both heterozygous SUR2wt/AV and homozygous SUR2AV/AV mice. In both
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 3. KATP channels in Kir6.1wt/VM and SUR2wt/AV ventricular myocytes. (A) Representative inside-out voltage-clamp recordings of KATP channel activity from acutely dissociated ventricular myocytes from WT (left) and Kir6.1wt/VM mice showing the response to MgATP (recording from –50 mV holding
potential). (B) Summary [MgATP]-response curves from excised patch experiments (IC50 values from individual experiments shown in inset; n = 10 for WT
and Kir6.1wt/VM from ≥ 3 mice each). (C) Representative inside-out voltage-clamp recordings of KATP channel activity from acutely dissociated ventricular
myocytes from WT (left, black), SUR2wt/AV (middle, orange), and SUR2AV/AV (right, red) mice showing the response to MgATP (recording from –50 mV holding
potential). (D) Summary MgATP dose-response curves from excised patch experiments shows increased MgATP IC50 in SUR2wt/AV and SUR2AV/AV mice (IC50
values from individual experiments shown in inset; n = 7 from WT, 9 from SUR2wt/AV, and SUR2AV/AV, from ≥ 3 mice each). Statistical significance was determined by multiway ANOVA followed by t test pairwise comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.017). *P < 0.05.

cases, basal KATP activation was also increased in whole-cell patch-clamp recordings from isolated VSMCs
(~1.5-fold and ~2.2-fold increases for SUR2wt/AV and SUR2AV/AV, respectively) (Figure 2, D and E). Glibenclamide reduced currents to near basal levels and, again, inclusion of 5 mM ATP in the pipette solution abolished basal K+ conductances (Figure 2E), confirming that the increase observed in SUR2[A478V]
VSMCs was due to elevated basal KATP activity. Notably, the KATP GOF in VSMCs from both SUR2wt/AV
and SUR2AV/AV mice was less than that observed in Kir6.1wt/VM mice, which is consistent with the effect of
these 2 substitutions in recombinantly expressed KATP channels (21, 24).
Nucleotide regulation of native KATP channels in the heart was assessed using excised, inside-out
patch-clamp recordings from acutely dissociated ventricular myocytes. Consistent with the prevailing evidence that ventricular KATP channels are composed predominantly of Kir6.2/SUR2A subunits (i.e., that
Kir6.1 is not present in these channels), there was no difference between sensitivity of WT or V65M channel activity to MgATP (Figure 3, A and B), which provides a combined assessment of ATP inhibition and
Mg-nucleotide activation of channels. In contrast, excised patch-clamp recordings from SUR2wt/AV and
SUR2AV/AV ventricular myocytes revealed right-shifted MgATP sensitivity (~2- and ~3.5-fold increases in
IC50, respectively; Figure 3, C and D), as predicted, given that SUR2 is expressed in ventricular myocytes
(15). Thus, in both VSMCs and ventricular myocytes a progressive increase in GOF was observed through
heterozygous and homozygous SUR2[A478V] mice. Taken together, these data confirm the expected
molecular consequences of the Kir6.1[V65M] substitution, i.e., that it results in marked GOF of VSMC
KATP, but has no significant effect on cardiomyocyte KATP channels, whereas the SUR2[A478V] substitution results in GOF of KATP channels in both VSMCs and ventricular myocytes.
We subsequently analyzed cellular, organ, and whole-animal phenotypes of the different genotypes.
Despite the above qualitatively different outcomes for ventricular KATP properties in the Kir6.1[V65M]
and SUR2[A478V] animals, all of the subsequent features described below were qualitatively similar in
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 4. The effects of KATP gain of function on vascular structure and function in Kir6.1wt/VM. (A) Left: Isolated
descending thoracic aortas show significant gross enlargement in Kir6.1wt/VM (middle). Sagittal 2D echocardiographic
images of the aortic arch reveal significant dilation in Kir6.1wt/VM mice (aortic boundaries indicated by dashed lines).
Right: Measurements of aortic diameter derived from 2D sagittal echocardiographic imaging at different points around
the aortic arch in WT (black) and Kir6.1wt/VM mice (blue). STJ, sinotubular junction; AA, ascending aorta; Arch, aortic arch;
DA, descending aorta; as shown in inset; n = 5). (B) Vessel compliance measurements from pressurized carotid arteries
of WT (black) and Kir6.1wt/V (blue) mice (n = 4 for WT, n = 7 for Kir6.1wt/VM). (C) Representative blood pressure measurements from anesthetized mice showing decreased basal systemic pressures in Kir6.1wt/VM mice and blunted response
to the KATP channel activator pinacidil. (D) Summary data showing systolic (left) and diastolic (right) pressures from
anesthetized mice (n = 9 for WT and 6 for Kir6.1wt/VM). (E) Telemetric measurements of mean arterial pressure from
ambulatory WT and Kir6.1wt/VM mice (n = 5 for both WT and Kir6.1wt/VM). Statistical significance was determined by multiway ANOVA followed by t test pairwise comparison with Bonferroni’s correction for multiple comparisons. Adjusted α =
0.013 (A), 0.007 (B), 0.013 (D), and 0.025 (E). *P < 0.05; **P < 0.01.

both Kir6.1[V65M] and SUR2[A478V] animals, but they were more marked in the former. Therefore,
we first present in detail the findings from Kir6.1[V65M] animals, and then present parallel data from the
SUR2[A478V] animals.
Vascular consequences of KATP GOF. CS patients exhibit dilated and tortuous blood vessels, reduced
blood pressure, and decreased pulse wave-velocity (4, 25), suggestive of a chronically relaxed, compliant
vasculature. In Kir6.1wt/VM mice, marked changes in gross vascular structure were observed, including significantly increased aortic diameters (ranging from ~15% to 70% increases around the proximal aorta, not
significant at the aortic arch), as measured in vivo by echocardiographic imaging and directly on isolated
tissue (Figure 4A). Assessment of pressurized carotid arteries, reflecting noncontractile biomechanical
properties of the vessels, revealed significantly increased arterial diameters across the full range of physiological pressures, and increased compliance (Figure 4B).
Marked reduction (~20–25 mmHg) of both systolic and diastolic basal blood pressures were observed
in anesthetized 3-month-old Kir6.1wt/VM mice (Figure 4C). Acute administration of pinacidil, which reduces
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 5. Cardiac hypertrophy in the Kir6.1wt/VM mouse. (A) Left: Gross heart size is increased in Kir6.1wt/VM mice.
Right: Heart weight normalized to tibia length (HW/TL; mg/mm; n = 11 for WT and 12 for Kir6.1wt/VM). (B) Cardiomegaly results from cellular hypertrophy as indicated by increased cell capacitance (measured from whole-cell voltageclamp recordings of isolated ventricular myocytes (n = 11 for WT and 16 for Kir6.1wt/VM) and (C) from measurements
of cell surface area (CSA) from H&E-stained ventricular tissue (n = 116 cells from 3 mice for WT and 69 cells from 3
mice for Kir6.1wt/VM). (D) Parasternal long-axis echocardiographic imaging shows increased left ventricle (LV) internal
diameter and wall thickness in Kir6.1wt/VM (endo- and epicardial boundaries indicated by white or blue lines for WT
and Kir6.1wt/VM, respectively). (E) M-mode echocardiographic quantification of LV mass (LVM; far left), LV internal
diameter (LVID; middle left), LV posterior wall (LVPW; middle right), and intraventricular septum (IVS; far right)
are increased in Kir6.1wt/VM mice (n = 5 for both). Statistical significance determined by t test for A, C, and LVM (in
E). For LVID, LVPW, and IVS in E, statistical significance was determined by multiway ANOVA followed by t test
pairwise comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.025). *P < 0.05.

blood pressure by activation of smooth muscle KATP in WT mice, was severely blunted in Kir6.1wt/VM animals
(Figure 4, C and D), reflective of the high basal KATP activity and consequently reduced additional activation by
pinacidil that is seen in isolated VSMCs (Figure 2). In agreement with data from the anesthetized mice, ambulatory telemetric recordings also showed approximately 30-mmHg decreases in blood pressure in Kir6.1wt/VM
mice at both night and day, although the difference was not significant during the daytime (Figure 4E).
Therefore, Kir6.1wt/VM mice display dilated, compliant arterial vessels resulting in hypotension, mirroring clinical observations in CS patients (4, 25).
Cardiac hypertrophy in Cantu mice. Cardiomegaly is a consistent finding in CS patients (25) and is dramatically recapitulated in adult Kir6.1wt/VM mice, which show approximately 1.7-fold increases in heart
weight (Figure 5A). Estimates of ventricular myocyte size, both from cell capacitance, a correlate of cell
membrane surface area, in whole-cell patch clamp recordings of isolated myocytes (Figure 5B), and from
H&E-stained ventricular tissue cross sections (Figure 5C), indicate that the increased cardiac mass arises
from equivalent cellular hypertrophy.
Echocardiographic imaging in vivo also demonstrates an approximately 2-fold increase in left ventricle (LV) mass in Kir6.1wt/VM mice, with dilated LV chamber diameters (~30% increase) along with
approximately equivalent increases in LV posterior wall and intraventricular septal thickness, compared
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 6. Aortic insufficiency and aortic regurgitation in the
Kir6.1wt/VM mouse. (A) Echocardiographic imaging in diastole reveals
aortic valve insufficiency (AI; aortic regurgitation) in 4 of 5 Kir6.1wt/VM
mice tested (AI not observed in any WT mice; n = 5), see also
Supplemental Video 1. (B) 2D color Doppler echocardiographic imaging in systole shows aortic valve stenosis in 4 of 5 Kir6.1wt/VM but 0
of 5 WT mice (see also Supplemental Video). In A and B, statistical
significance was determined by t test. *P < 0.05. (C) Correlation of
AI with aortic diameter at the sinotubular junction (STJ) (left); left
ventricular mass (LVM; derived from echocardiography) and aortic
valve pressure gradient (middle); and LVM and AI area (right) in
Kir6.1wt/VM mice. R denotes Pearson’s correlation coefficient.

with WT (Figure 5, D and E). Consequently, relative wall thickness (RWT) was not significantly different
in Kir6.1wt/VM mice (RWT for WT 0.57 ± 0.02 mm; for Kir6.1wt/VM 0.52 ± 0.03 mm; P = 0.1), although
suggestive of a mild prevailing eccentric hypertrophy.
Therefore, despite Kir6.1wt/VM cardiac myocytes showing essentially normal KATP channels, Kir6.1wt/VM
hearts display chamber dilation and marked cardiac enlargement as a result of cellular hypertrophy, again
consistent with echocardiographic findings in CS patients (3, 25).
Aortic regurgitation and stenosis in Kir6.1wt/VM mice. Cardiac hypertrophy can be associated with valvular
defects and/or aortic insufficiency (AI), as has been reported in CS patients (2, 6). Aortic valve function
was assessed in vivo by echocardiography. AI and aortic stenosis (AS) of variable extent were observed in
color Doppler echocardiographic imaging in 4 of 5 Kir6.1wt/VM mice, with 0 of 5 WT littermate controls
affected (Figure 6, A and B). The extent of AI was strongly correlated with the measured aortic diameter
(sinotubular junction diameter, Figure 6C). In addition, relative AS was apparent in 4 of 5 Kir6.1wt/VM mice,
in which qualitative valve thickening and restricted leaflet opening were observed (Figure 6, A and B). This
was accompanied by elevated mean pressure gradients across the valve in the Kir6.1wt/VM mice (Figure 6,
A and B, and Supplemental Video 1; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.121153DS1).
This combination of AI and increased preload, alongside stenotic or dysfunctional valves with resultant increases in afterload, could contribute to the LV hypertrophy and chamber dilation that are observed.
However, there was only a weak correlation between AI or mean gradient and LV mass (Figure 6C), suggesting that both AI and valvular defects may not be primary drivers of hypertrophy in these mice.
Increased cardiac output in Kir6.1wt/VM mice. In echocardiographic recordings, fractional shortening was
not different from WT, but cardiac output was dramatically (~65%) higher, due to equivalently greater
stroke volume (Figure 7, A–E). There was a significantly (~80%) higher rate of LV emptying (dV/dT max)
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 7. Cardiac function in WT and Kir6.1wt/VM mice. (A) Representative M-mode echocardiographic imaging of WT
(top) and Kir6.1wt/VM mice (bottom) showing dilated left ventricle chambers and increased wall diameters. d, diastole;
s, systole; IVS, interventricular septum; LVID, left ventricular internal diameter; LVPW, left ventricular posterior wall.
(B) Left ventricle (LV) fractional shortening (FS) is unchanged in Kir6.1wt/VM as determined from M-mode echocardiograms (n = 5 for both). (C) Stroke volume (SV) is increased in Kir6.1wt/VM mice (n = 5 for both). (D) Heart rate (HR) is
unchanged in lightly anesthetized Kir6.1wt/VM mice during echocardiographic investigation (n = 5 for both genotypes).
(E) Cardiac output is markedly increased in Kir6.1wt/VM mice due to increased SV and preserved FS. (F) Peak myocardial strain rate (dV/dT max) was increased in Kir6.1wt/VM mice as determined from speckle tracking measurements.
(G) Left: Representative ECG recordings from awake WT (black) and Kir6.1wt/VM (blue) mice. Right: Summary HR, RRinterval, QT duration, and corrected QT (QTc) from WT and Kir6.1wt/VM mice (data shown as mean ± SEM; n = 7 for WT,
n=11 for Kir6.1wt/VM). Statistical significance determined by t test. *P < 0.05.

in Kir6.1wt/VM mice (Figure 7F). This combination of features is consistent with the characteristic highoutput cardiac phenotype observed in CS patients (25) that is distinct from typical hypertrophic or dilated
cardiomyopathies in which systolic function is impaired. It is consistent with earlier studies of transgenic
mice, which showed that expression of KATP GOF subunits in either the myocardium or in VSM both result
in hypercontractile phenotypes in the heart (25, 26). These outcomes are not directly predicted from any
expected electrophysiological consequences of cardiac KATP channel GOF. Baseline surface ECG recordings from ambulatory Kir6.1wt/VM mice were not markedly different from WT, consistent with patch-clamp
studies of isolated ventricular myocytes showing no major changes in Kir6.1wt/VM cardiac KATP function
(Figure 3). Therefore, we suggest that the high-output, enlarged heart observed in Kir6.1wt/VM mice may
result not from a primary effect on cardiac KATP but rather from systemic feedback mechanisms that counter hypotension arising from vascular KATP GOF.
Key CS features are common to both Kir6.1 and SUR2 GOF mutant mice. Basal systolic and diastolic
blood pressures were also decreased relative to WT, in both anesthetized SUR2AV/AV and SUR2wt/AV mice.
Ambulatory blood pressures also decreased in both, but only significantly so in SUR2AV/AV mice (Figure
8, A and B). As seen in Kir6.1[V65M] animals, the relative blood pressure–lowering effect of pinacidil
was again reduced in SUR2wt/AV, and more so in SUR2AV/AV (Figure 8, A and C), to the extent that,
intriguingly, the lowest pressure achieved with pinacidil was actually higher in SUR2wt/AV than WT, and
even more so in SUR2AV/AV (Figure 8, A and C), the implications of which are considered in the Discussion. As observed in Kir6.1wt/VM mice, there were clear trends towards progressively increased vascular
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 8. Vascular consequences in SUR2wt/AV mice. (A) Representative blood pressures in anesthetized mice showing decreased basal pressures in SUR2wt/AV and SUR2AV/AV mice and blunted response to the KATP channel activator
pinacidil. (B) Telemetric measurements of mean arterial pressure from ambulatory WT (black), SUR2wt/AV (orange), and
SUR2AV/AV (red) mice show decreased blood pressure in SUR2AV/AV mice (n = 3 for each genotype). (C) Summary data
showing basal and pinacidil-reduced systolic (left) and diastolic (right) pressures from anesthetized WT, SUR2wt/AV,
and SUR2AV/AV mice (n = 6 for WT, 5 for SUR2wt/AV, and 6 for SUR2AV/AV). (D) Isolated descending thoracic aortae show
progressive dilation in SUR2wt/AV and SUR2AV/AV mice. (E) Aortic diameter derived from 2D sagittal echocardiographic
imaging at different points around the aortic arch in WT (black), SUR2wt/AV (orange), and SUR2AV/AV (red). STJ, sinotubular junction; AA, ascending aorta; Arch, aortic arch; DA, descending aorta; as shown in inset; n = 3 each). (F) Vessel
compliance in pressurized carotid arteries of WT (black), SUR2wt/AV (orange), and SUR2AV/AV (red) mice reveal increased
diameters in mutant mice across full pressure range (n = 4 for WT, 5 for SUR2wt/AV, and 5 for SUR2AV/AV). Statistical
significance was determined by multiway ANOVA followed by t test pairwise comparison with Bonferroni’s correction for
multiple comparisons. Adjusted α = 0.008 (B), 0.006 (C), and 0.004 (F). **P < 0.01.

diameters, both in vivo in echocardiographic imaging and ex vivo in pressurized compliance measurements on isolated vessels, for SUR2wt/AV and SUR2AV/AV mice (Figure 8, D–F).
Marked cardiomegaly was also observed in both SUR2wt/AV and SUR2AV/AV mice (~1.2- and ~1.6-fold
increases, respectively; Figure 9A), which cell surface area measurements again revealed to result from cellular hypertrophy (Figure 9B). Again, echocardiographic measurements revealed maintained fractional shortening, despite LV dilation, while cardiac output and stroke volume were significantly increased (Figure 9, C–E).
Reflecting the generally weaker phenotype in the SUR2-mutant mice, AI was not observed in any of 5 SUR2wt/AV
mice, but was observed in 1 of 5 SUR2AV/AV mice, while no littermate controls were affected (data not shown).

Discussion
The pathophysiological effects of KATP GOF in CS. Autosomal dominant GOF mutations in KCNJ8 and
ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of KATP potassium channels, have now been
established as the genetic basis of CS (20–24, 27). In addition to hypertrichosis and coarse facial appearance, CS patients are characterized by a constellation of cardiovascular features, including marked
cardiomegaly, vascular dilation and tortuosity, low blood pressure, persistence of fetal circulation, and
pulmonary hypertension (2–6). While low blood pressure is a directly predictable primary consequence
of vascular KATP GOF (Figure 10A), few of the other features, particularly the cardiac enlargement,
have a ready explanation, and no direct causal association between the genetic basis and these outcomes has been established.
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 9. Cardiac hypertrophy in SUR2wt/AV mice. (A) Left: Gross heart size is increased in SUR2wt/AV and SUR2AV/AV mice.
Right: Heart weight normalized to tibia length (HW/TL; mg/mm; n = 10 for WT, 14 for SUR2wt/AV, and 14 for SUR2AV/AV). (B)
Cell surface area (CSA) measurements from H&E-stained ventricular sections shows cellular hypertrophy in SUR2AV/AV mice
(n = 45 cells from 3 mice for WT, 162 cells from 3 mice for SUR2wt/AV, and 124 cells from 3 mice for SUR2AV/AV). (C) Fractional
shortening is unchanged in SUR2wt/AV and SUR2AV/AV mice as determined from M-mode echocardiographic imaging. (D) Cardiac output is significantly increased in both SUR2wt/AV and SUR2AV/AV mice due to increased stroke volume (E) (n = 4 for WT
and SUR2wt/AV and 5 for SUR2AV/AV). Statistical significance was determined by multiway ANOVA followed by t test pairwise
comparison with Bonferroni’s correction for multiple comparisons (adjusted α = 0.017). *P < 0.05.

In generating animal models in which specific CS mutations are introduced into the equivalent endogenous loci in the mouse genome, we can therefore directly test the causal association. The above studies demonstrate that CS-associated GOF substitutions in both Kir6.1 and SUR2 cause a common constellation of complex cardiovascular features, including increased vascular dilation and compliance, low blood pressure, cardiac
hypertrophy, and increased cardiac output. As such, our mouse models recapitulate the key cardiovascular
features observed clinically in CS (2, 3, 6). We observe a clear correlation between the extent of basal vascular
KATP channel activation and the severity of cardiovascular abnormalities through SUR2wt/AV, SUR2AV/AV, and
Kir6.1wt/VM mice (Figure 10B). Notably, this phenotypic severity also correlates with the previously reported
biophysical effects of these mutations (21, 22, 24). In the compound heterozygous Kir6.1wt/VM/SUR2wt/AV and
homozygous Kir6.1VM/VM animals, the presumably even stronger molecular phenotype results in early death.
This precluded detailed assessment of cardiovascular outcomes, but revealed what may be lethal effects of
resultant gastrointestinal insufficiency. Interestingly, human CS is likely to represent a more severe clinical
categorization within a spectrum of Kir6.1/SUR2 GOF–associated disorders that also includes acromegaloid
facial appearance (AFA) syndrome and hypertrichosis with acromegaloid facial features (HAFF) syndrome,
in which cardiovascular abnormalities are not reported (28). The severity of human disease may directly correlate with effects on molecular function but some of the same mutations have been reported in both CS and
AFA/HAFF patients, so drawing quantitative phenotype-to-genotype comparisons may prove difficult and
will require more detailed investigation of multiple mutations (20, 27–29).
Vascular consequences of KATP GOF — primary CS pathological consequences. That deliberate introduction
of these GOF mutations in both ABCC9 and KCNJ8 genes converge to the same pathophysiology conclusively demonstrates that the associated pathologies, as observed in CS, result from changes in the KATP
channel complex that is generated by SUR2 and Kir6.1 protein association (5, 22). It further indicates
that the primary consequences must arise in tissue(s) in which both Kir6.1 and SUR2 are expressed.
Kir6.1 and SUR2 are clearly both expressed in VSMCs (15, 30), but the situation in cardiac myocytes
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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Figure 10. Progressive cardiovascular consequences of Cantu syndrome. (A) The primary consequence of KATP GOF in
the vasculature is reduced excitability, leading to functional and structural vasodilation, low blood pressure, and underperfusion. Secondarily, this leads to a compensatory cardiac hypertrophy and hypercontractility. (B) These features
are present in even mild (e.g., SUR2wt/AV) CS models, but are exacerbated in more severe genotypes (e.g., Kir6.1wt/VM and
SUR2AV/AV). The latter genotypes are associated with premature death, and very early death occurs immediately after
weaning in the most severe genotypes (e.g., SUR2wt/AV/Kir6.1wt/VM and Kir6.1VM/VM).

is less clear. Most studies indicate that SUR2 is the primary sulfonylurea receptor in the ventricle, and
that Kir6.2 is the pore-forming subunit (31), evidence for Kir6.1 expression being mostly limited to isolated reports of expression in conducting tissue (32). That the most severe CS features are present in
Kir6.1[V65M] mutant mice — in which KATP GOF is observed in VSMCs but not ventricular myocytes
— therefore points to a cardinal role for a non–cardiac muscle origin of the ensuing pathophysiology.
Increased KATP activity in vascular smooth muscle is predicted to decrease cellular excitability and contractility. Consistent with this, SUR2-selective KATP openers acutely decrease vascular tone and lower
blood pressure in WT animals (33). Enhanced basal vascular KATP activation, as was present in VSMCs
from both Kir6.1[V65M] and SUR2[A478V] animals, would thus directly lead to reduced vessel contractility, explaining the lowered blood pressure and reduced response to pinacidil in the whole animal. In
SUR2[A478V] animals, the maximum KATP overactivity in pinacidil is greater than WT in heterozygous
and greatest in homozygous animals, yet the blood pressure in the presence of pinacidil is actually lowest
in WT and highest in homozygous animals (Figure 8), counter to naive expectations.
In addition, we see that passive vessel compliance is increased in both genotypes. Increased vessel
compliance may reflect increased elastin production in smooth muscle, as has been reported in response to
pharmacological activators of KATP channels in cultured smooth muscle cells (34), and in the rat aorta (35).
It should be noted that endothelial KATP channels have also been implicated in blood pressure control (36,
37), and in angiogenesis (38–40). Thus, endothelial dysfunction may also contribute to decreased vascular
tone and vessel tortuosity in CS, but this remains to be fully elucidated.
AS, AI, and valvular defects are also reported in association with human CS (2, 6). Here we demonstrate
functional defects in the aortic valve of Kir6.1wt/VM mice alongside AI and apparent aortic valve stenosis.
As extensive dilation is observed throughout the vasculature in CS patients (4), and in the Cantu mice,
we hypothesize that AI may be a direct consequence of aortic root dilation. Consistent with this, there is
a marked correlation between aortic diameter and AI in Kir6.1wt/VM mice. The complex combination of
insight.jci.org   https://doi.org/10.1172/jci.insight.121153
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mutually exacerbating AI and AS would be predicted to increase LV preload and afterload, respectively, and
thence to increase cardiac hypertrophy (see below).
Structural and electrical remodeling in the heart — secondary consequences of KATP GOF. In contrast to the
observed vascular manifestations, there are no ready explanations to link KATP GOF and the cardiac features of CS. The naive expectation of KATP GOF in the heart itself would be action potential shortening, or
slowing of the cardiac rate, either or both of which will lead to net reduction in cardiac output. However,
in CS patients (25), and in both Kir6.1[V65M] (Figure 5) and SUR2[A478V] (Figure 9) mutant mice, we
observe profound cardiac enlargement and enhanced cardiac output. This is despite the different effects of
the Kir6.1 and SUR2 mutations on ventricular KATP channel properties (Figure 3). Hence we suggest that
cardiac enlargement is likely to predominantly arise independently of ventricular KATP activity, and to instead
be a secondary consequence of vascular dysfunction (Figure 10A). The enlargement observed in the Cantu
hearts includes increased LV internal dimensions and wall thickness. This combination is distinct from typical
eccentric or concentric hypertrophies arising from volume or pressure overload, respectively, and functionally
resembles physiological, exercise-induced, hypertrophy, in which fractional shortening is maintained (41).
Long-term effects of CS pathophysiology and implications. The CS combination of cardiac cellular hypertrophy, with chamber and wall enlargement, AI, enhanced cardiac contractility, together with vascular
dilation and low blood pressure may represent a unique pathophysiological constellation, distinct from
other commonly defined conditions of myocardial hypertrophy. Little is yet known about the progressive
nature of CS, but it is notable that the majority of diagnosed patients are children or young adults. Whether
this reflects the recent recognition of the condition itself (the genetic basis was only discovered in the last
6 years) and the success of modern palliative therapies, or is an indication of poor long-term prognosis,
remains to be elucidated. Cardiac output is elevated in 3-month-old Cantu mice (Figures 5 and 7), but further studies will be required to determine whether the various cardiac abnormalities result in a progressive
functional decline with long-term aging, such as is observed in other forms of pathological hypertrophy.
First demonstrated in mice almost 20 years ago (42), recognition of the causal role of GOF mutations in the Kir6.2/SUR1 proteins in neonatal diabetes (43) has led to dramatically improved understanding of the pathophysiological consequences (44), as well as a revolution in therapy using KATP
channel–blocking sulfonylurea drugs (45, 46). The Cantu mouse models we describe here will provide
the opportunity for longitudinal analysis of CS pathophysiology over time, as well as an appropriate
preclinical model in which to test the efficacy of KATP inhibitors (such as sulfonylureas) or other potential
therapies, for what is currently an untreatable syndrome. Moreover, as these mice now confirm a causal
link between KATP GOF mutations and a host of complex cardiovascular outcomes, they point the way to
future studies aimed at understanding the broader consequences of pathophysiological changes in KATP
channel resulting from nongenetic causes, such as altered cell signaling.

Methods
Study approval
Studies were performed in compliance with the standards for the care and use of animal subjects defined in
the NIH Guide for the Care and Use of Laboratory Animals (33) and were reviewed and approved by the
Washington University Institutional Animal Care and Use Committee.

CRISPR/Cas9 genome editing
Using CRISPR/Cas9–mediated genome engineering technology (47), we generated knockin mice carrying
human GOF mutations in the ABCC9 or KCNJ8 genes, which encode the accessory SUR2 and the pore-forming Kir6.1 subunits of the KATP channel, respectively. The guide RNA (gRNA) target sequences were predicted
using the MIT CRISPR design tool (http://crispr.mit.edu). abcc9 gRNA (5′ CATTGCCACGAAGCTGGCGG 3′) or kcnj8 gRNA (5′ ACGCCACTTCAGGTCTACCA 3′) were subcloned into BbsI-digested plasmid
pX330 (Addgene, 42230). sgRNA activity was validated in vitro by transfection of N2A cells using Roche
Xtremegene HP, followed by T7E1 assay (NEB). T7 sgRNA template and T7 Cas9 template were prepared
by PCR amplification and gel purification, followed by RNA in vitro transcription with the MEGAshortscript
T7 kit (gRNA) or the T7 mMessage mMachine Ultra kit (Cas9). After transcription, RNA was purified with
the Megaclear kit (Life Technologies). Single-stranded oligodeoxynucleotide (ssODN) donor DNAs (200 nt)
with the appropriate mutation centered within the ODN were synthesized by IDT as ultramer ODNs.
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B6CBA F1/J female mice (3–4 weeks old; Jackson Laboratory) were superovulated and mated
overnight with B6CBA F1/J male mice (>7 weeks old). Zygotes were harvested from the ampullae of
superovulated females and placed in potassium-supplemented simplex optimized medium (KSOM;
MR106D) before microinjection. Microinjection of the Cas9, sgRNA, and ssDNA template (at a
final concentration of 50 ng/μl Cas9 WT RNA, 25 ng/μl gRNA, and 20 ng/μl ssODN DNA) was
performed in flushing holding medium (FHM; MR-024-D; EmbryoMax; Millipore). After injection,
zygotes were incubated at 5.5% CO2 at 37°C for 2 hours, and surviving embryos were transferred to
ICR recipient mice by oviduct transfer. Founders were identified using Qiagen pyrosequencer and
Pyromark Q96 2.5.7 software. We identified 12 positive founder animals carrying CS mutation mouse
SUR2[A476V] (equivalent to human SUR2[A478V]), and 2 positive founder animals carrying the CS
mutation Kir6.1[V65M]. All founders were viable and fertile. Successful mutation of founder (F0)
mice was verified by Sanger sequencing of genomic DNA and mutant mice were subsequently crossed
with C57BL/6J mice to generate heterozygous F1 Kir6.1wt/VM and SUR2wt/AV lines. PCR was used to
generate amplicons of KCNJ8 and ABCC9 spanning >1 kb on either side of the introduced mutation,
from gDNA isolated from mouse tails, and resultant PCR products were sequenced to confirm absence
of unintended additional mutations. After verification, one F1 animal from one line of each genotype
was selected and further crossed against C57BL/6J to generate F2 heterozygous animals, which were
intercrossed to generate F3 heterozygous and heterozygous as well as WT littermates that were used
in experiments.

Patch-clamp electrophysiology
Isolated VSMCs. Mice were anesthetized with 2.5% avertin (10 ml/kg, i.p.; Sigma-Aldrich) and the
descending aorta was rapidly dissected and placed in ice-cold physiological saline solution (PSS) containing (in mM) 134 NaCl, 6 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with
NaOH. Smooth muscle cells were enzymatically dissociated in dissociation solution containing (in mM)
55 NaCl, 80 sodium glutamate, 5.6 KCl, 2 MgCl2, 10 HEPES, and 10 glucose, pH 7.3 with NaOH, then
placed into dissociation solution containing papain μg/ml 12.5, 1 mg/ml dithioerythritol, and 1 mg/ml
BSA for 25 minutes (at 37°C), before transfer to dissociation solution containing 1 mg/ml collagenase
(type H/F = 1:2), and 1 mg/ml BSA for 5 minutes (at 37°C). Cells were dispersed by gentle trituration
using a Pasteur pipette, plated onto glass coverslips on ice, and allowed to adhere for more than 1 hour
before transfer to the recording chamber.
Whole-cell KATP currents were recorded using an Axopatch 200B amplifier and Digidata 1200 (Molecular Devices). Recordings were sampled at 3 kHz and filtered at 1 kHz. Currents were initially measured at a
holding potential of –70 mV in a high-Na+ bath solution containing (in mM) 136 NaCl, 6 KCl, 2 CaCl2, 1
MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with NaOH before switching to a high-K+ bath
solution (140 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, with pH adjusted to 7.4 with KOH) in the
absence and presence of pinacidil and glibenclamide as indicated. The pipette solution contained (in mM)
110 potassium aspartate, 30 KCl, 10 NaCl, 1 MgCl2, 10 HEPES, 0.5 CaCl2, 4 K2HPO4, and 5 EGTA, with
pH adjusted to 7.2 with KOH.
Isolated ventricular myocytes. Adult mice were anesthetized using 2.5% Avertin (10 ml/kg), and the heart
and ascending aorta were removed and immersed in ice-cold calcium-free Wittenberg Isolation Medium
(WIM; in mM): 116 NaCl, 5.4 KCl, 8 MgCl2, 1 NaH2PO4, 1.5 KH2PO4, 4 NaHCO3, 12 glucose, 21 HEPES,
2 glutamine plus essential vitamins (GIBCO), and essential amino acids (GIBCO) (pH 7.40). The heart was
cannulated via the aorta and Langendorff perfused with WIM for 5 minutes at 37°C, followed by 20-minute perfusion of WIM supplemented with 270 units/ml of collagenase type 2 (Worthington Biochemical)
and 10 μM CaCl2 at 37°C. The heart was then transferred to WIM containing 50 mg/ml BSA, 12.5 mg/ml
taurine, and 150 μM CaCl2, and ventricular tissue was manually dissociated using forceps before single-cell
dissociation by trituration with a fire-polished Pasteur pipette.
Inside-out patch-clamp recordings were made in symmetrical KINT solution that contained (in mM)
140 KCl, 10 HEPES, 1 EGTA (pH 7.4 with KOH). Varying MgATP concentrations were applied using
a Dynaflow Resolve perfusion chip (Cellectricon). MgCl2 was added to each solution to achieve a free
[Mg2+] of 0.5 mM according to calculations using CaBuf (Katholieke Universiteit Leuven). Membrane
currents were sampled at 3 kHz, filtered at 1 kHz, at a holding potential of –50 mV using an Axopatch
700B amplifier and Digidata 1200. KATP channel currents in solutions of varying nucleotide concentrations
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were normalized to the basal current in the absence of nucleotides and dose-response data were fit with a
4-parameter Hill fit according to the equation: Normalized current = Imin + (Imax – Imin)/(1 + ([X]/IC50)H),
where the current in Kint = Imax = 1, Imin is the normalized minimum current observed in MgATP, [X] refers
to the concentration of MgATP, IC50 is the concentration of half-maximal inhibition, and H denotes the
Hill coefficient.

Arterial compliance
After mice were euthanized under isoflurane anesthesia, the left common carotid arteries of 3-week-old
mice were excised and placed in PSS containing 130 mM NaCl, 4.7 mM KCl, 1.18 mM MgSO4-7H2O,
1.17 mM KH2PO4, 14.8 mM NaHCO3, 5.5 mM dextrose, and 0.026 mM EDTA (pH 7.4). The vessels
were then cleaned from surrounding fat, mounted on a pressure arteriograph (Danish Myo Technology)
and maintained in PSS at 37°C. Vessels were visualized with an inverted microscope connected to a
charged-coupled device camera and a computerized system, which allows continuous recording of vessel diameter. Intravascular pressure was increased from 0 to 175 mmHg by 25-mmHg increments and
the vessel outer diameter was recorded at each step (12 seconds per step). The average of 3 measurements at each pressure was reported.

Blood pressure measurement
Mice were anesthetized with 1.5% inhaled isoflurane and restrained on a heating pad to maintain body
temperature. A 2- to 3-mm incision was made in the midline of the neck; the thymus and muscle were separated to expose the right carotid artery. A Millar pressure transducer (model SPR-671) was carefully inserted into the right carotid artery and moved to the ascending aorta. Systolic blood pressure, diastolic blood
pressure, and heart rate were recorded using the PowerLab data acquisition system (ADInstruments), and
data were analyzed using LabChart 7 (ADInstruments). For blood pressure measurements in conscious
mice, a radio-telemetry pressure transmitter (Data Science International, DSI) was surgically inserted into
the left carotid artery and moved to the ascending aorta, where blood pressures in day and night were
recorded by DSI data acquisition system after mice recovered from surgery.

Heart weight measurement and histology
Mice were anesthetized with 2.5% Avertin and hearts were excised and rinsed with PBS that contained
(in mM) 137 NaCl, 2.7 KCl, 10 Na2HPO4, and KH2PO4 (pH 7.4 with NaOH). The hearts were arrested
in diastole with 10% KCl, and blotted to remove excess liquid. Hearts were then weighed and weight
was normalized to tibia length. After weighing, the hearts were fixed in 10% buffered formalin for 24
hours, and embedded in paraffin. Sections (3 μm) were cut and stained with H&E for the morphometric analysis.

Echocardiography
Echocardiography was performed using a Vevo 2100 Imaging System (VisualSonics) equipped with a
30-MHz linear-array transducer according to previously published methods (48–50). Cardiac images
were obtained by a handheld technique using 100 mg/kg i.p. tribromoethanol anesthetic; aortic images were obtained under 1.5% inhaled isoflurane. M-mode images were used to make LV dimensional
measurements. Quantitative image analysis was also performed using a speckle-tracking algorithm to
obtain volumetric and strain data. Sagittal 2D images of the aortic arch were used to measure aortic
diameters at multiple levels and to obtain Doppler images for pulse wave velocity measurements.

Statistics
Unless otherwise noted, data were tested for statistical significance using t test or multiway ANOVA with
Bonferroni’s correction as applicable, and are presented as mean ± SEM. Unless otherwise noted, significance is denoted as P < 0.05.
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